Drug Profile
Pegfilgrastim biosimilar - Coherus BioSciences
Alternative Names: CHS-1701; Pegfilgrastim-cbqv; UDENYCA; UDENYCA ONBODY; UDENYCA® OBILatest Information Update: 26 Feb 2024
Price :
$50
*
At a glance
- Originator Coherus Biosciences
- Developer Coherus BioSciences
- Class Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Neutropenia
Most Recent Events
- 21 Feb 2024 Pegfilgrastim on-body injector (UDENYCA ONBODY™) is available in USA for Neutropenia (SC)
- 05 Oct 2023 Coherus BioSciences resubmits the Biological license application (BLA) supplement to the US FDA for on-body injector presentation of pegfilgrastim for Neutropenia
- 25 Sep 2023 Coherus BioSciences receives complete response letter from the FDA for on-body injector presentation of pegfilgrastim in Neutropenia